Welcome to Kenya Association of Pharmaceutical Industry


  Contact Us : info@kapikenya.org I Member Login

All Posts in Category: Media Brief

KAPI WEEKLY BRIEF: 15TH – 19TH FEBRUARY 2021

19th February 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • Novavax committed additional COVID-19 vaccine doses to COVAX for distribution to low and middle income countries bringing the total tally to 1.1B doses. (Endpoint News)
  • The USA plans to contribute $4 billion to COVAX in efforts to support vaccination in low income countries but has plans to control shipping of locally manufactured vaccines until the nation’s demands are met. (Bloomberg)
  • Pfizer Inc. plans to roll out a clinical trial for a booster to its vaccine shot in South Africa in response to the spreading more contagious variant. (Reuters). This follows laboratory studies that showed the S. African variant could reduce antibody protection from the Pfizer/BioNTech vaccine (Reuters)
  • Two Canadian researchers have urge for delay in administration of the second shot of the Pfizer/BioNTech vaccine which should be administered three to four weeks after the first one in efforts to extend supply to more people. (BioSpace)
  • Pfizer plans to roll out clinical trials of its vaccine in pregnant women in efforts to get data for improved care and protection for this sub-population in response to COVID-19. (NBC News)
  • The European Union launched the “HERA Incubator” as a blueprint for long-term health emergencies and a way to stop COVID-19 mutations. The incubator is set to receive €30 million from Horizon 2020. (Open Access Government)
  • The US National Institute for Health has reported that a new study, IMPAACT 2032, will analyze remdesivir in pregnant women to whom it has been prescribed for management of COVID-19 (Clinical Trials Arena)
  • WHO seeks $1.96 billion for the 2021 Strategic Plan for COVID-19 response following last year’s initial plan that outlined the path that countries should take to suppress transmission of the new coronavirus. (UN)
  • Africa is getting ready to roll out COVID-19 vaccines as reported by WHO African Regional representative Dr Moeti (WHO Africa)
  • MSF calls on wealthy nations & biopharmaceutical companies for immediate and equitable distribution of affordable and the right COVID-19 vaccines to Southern African countries. (MSF)
  • A new study looks at the probable benefit of probiotics in the management of COVID-19 given the emergence of new variants & broad spectrum of clinical disease witnessed with COVID-19. (News Medical)
  • Johnson & Johnson filed for approval of its vaccine in EU with decision probable by the middle of March according to drug regulators (Medical Xpress)
  • A research team have developed a machine learning solution aimed at identifying probable treatments for COVID-19 from those already in the market based on the disease profile and aging. (Health Europa)
  • The WHO approved AstraZeneca COVID-19 vaccine for emergency use (Wall Street Journal)
  • World Trade Organization (WTO) appoints Ngozi Okonjo Iweala as the Organizations 7th Director General (WTO)

Thank You!!!

Read More

KAPI WEEKLY BRIEF: 8TH – 12TH FEBRUARY 2021

12th February 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • A preliminary study in South Africa by University of Oxford and University of Witwatersrand have indicated inability of AstraZeneca/Oxford Vaccine to protect against mild and moderate forms of the new variant of the disease prevalent in South Africa. (The Wall Street Journal, Financial Times). On the backdrop of this, AstraZeneca and Oxford University have ventured into developing a new and improved vaccine with efficacy against the new COVID-19 variant in South Africa (Telegraph). The South African government now plans to give health workers the J&J vaccine instead (ABC News). This emerging evidence poses a challenge to other African countries on whether to use the AstraZeneca/Oxford vaccine as well (Financial Times).
  • The WHO have advised use of AstraZeneca/Oxford vaccine on all adults above 18years of age (Financial Times | UN News).
  • In efforts to boost EU COVID-19 Vaccine supplies, BioNTech reported having started production in their new facility in Germany (Medical Xpress)
  • Single dose of Pfizer vaccine shows signs of success in the UK which may make it feasible to extend gap between doses in a vaccination schedule (Financial Times)
  • Calling for an end to vaccine nationalism UNICEF Executive Director and WHO Director General urged governments to promote equitable access arguing that in this pandemic we have an option to win together or lose together. (WHO)
  • AstraZeneca plans to double up on their vaccine production to cover for shortfalls in supply that were witnessed at the start of the year. This was highlighted in the review of financial position for the previous year. (The Wall Street Journal)
  • Generic inhaled corticosteroid budesonide shows promise in treatment of COVID-19 in a small scale clinical trial (Pharma Phorum | Reuters)
  • There is a rising mortality as Africa marks one year since outbreak of COVID-19 on the backdrop of a surge in variants. (WHO African Region)
  • Dermapharm aims to start producing Pfizer vaccines at a second site in efforts to aid the drug maker meet its target of 2 billion doses by the end of the year. (Reuters)
  • Eli Lilly COVID-19 antibody combination gets FDA emergency authorization (Bloomberg)
  • Experts state that COVID-19 unlikely to have come from a lab following preliminary investigations (UN News)
  • Sinovac reports that their COVID-19 vaccine showed positive results in preventing hospitalization and death from two studies conducted in Brazil and Turkey (Reuters)
  • Pfizer vaccine effective against UK and South Africa variants of COVID-19 ( AA Com)
  • Moderna vaccine effective against new variants of the virus (News Medical Life Sciences)

Thank You!!!

Read More

KAPI WEEKLY BRIEF: 1ST – 5TH FEBRUARY 2021

5th February 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • COVAX Publishes first interim distribution forecast for COVID-19 Vaccines aimed at providing governments and health systems with the information they need to plan their national vaccination programmes. (GAVI| COVAX| Reuters |COVAX Supply Forecast)
  • AstraZeneca and Oxford University expect to have new generation vaccine against COVID-19 variants by autumn this year. (Reuters)
  • The African Union urges for equitable vaccine access and debt relief for member countries. (CGTN)
  • Mike Bloomberg and Dr. Tedros Adhanom call for global focus on Non Communicable Diseases (NCDs) to save lives from COVID-19. This came after confirmation of Bloomberg as the WHO Global Ambassador for NCDs and Injuries for the third term.(Mirage News)
  • The World Cancer Declaration: time to consolidate wins and work towards 2025. (Lancet Oncology)
  • The biopharmaceutical industry supports the establishment of African Medicines Agency (AMA) and calls on governments to ratify the AMA Treaty towards a unified continental regulatory framework. (IFPMA)
  • GSK and CureVac to start working on a next generation vaccine targeting emerging variants of the coronavirus with likelihood of being ready next year. (PharmaPhorum)
  • A new trial testing whether giving people two different COVID vaccines as first and second doses can give effective protection as using the same formulation has started. (CITYA.M)
  • A study shows that the Pfizer vaccine single shot is 90% effective after 21 days. (Medical Express)
  • Ebonyi State, South East Nigeria launched a pharmaceutical manufacturing park “Pharmacity” aimed at being the hub of quality medicine production in the whole of West Africa. (Pharma News)
  • Johnson & Johnson applies to the US FDA for Emergency Use Authorization for their vaccine which was reported to have a 66% efficacy in international clinical trials (The Wall Street Journal)
  • Africa expects to start receiving millions of vaccine doses from COVAX in February as reported by the WHO Africa Regional Office Director. (WHO |CGTN)

Thank You!!!

Read More

KAPI WEEKLY BRIEF: 25TH TO 29TH JANUARY 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • The Serum Institute of India (SII), the world’s largest vaccine maker has applied to local authorities to conduct small domestic trials of Novavax Inc’s. COVID-19 Vaccine found to be 89.3% effective in UK trial. (Reuters |The Guardian)
  • The Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members calls for structured investment in COVID-19 vaccines and therapeutics for low and middle income countries. (The Lancet)
  • World Health Organization (WHO) and the International Development Innovation Alliance (IDIA) signs a strategic collaborative agreement to support scaling up of healthcare innovations in low and middle income countries (Health Europa)
  • Policies geared towards reduction of fomite disinfection to recommended levels are critical in the fight against antimicrobial resistance (AMR). This is acknowledging potential transfer of resistance from bacterial pathogens especially on the backdrop of widespread disinfection and use of alcohol based hand sanitizers to contain spread of COVID-19. (Science)
  • Vaccines prevented 37 million deaths in the last 20years in LMIC and are projected to save 32 million more lives by 2030. This is why we must invest in vaccination programmes. (Mirage News)
  • WHO announces updated definitions for extensively drug-resistant tuberculosis (XDR-TB) to help precisely define patients who need complex treatment regimens, lead to better surveillance, reporting and monitoring of drug-resistant TB. (WHO)
  • Pfizer vaccine found to be only less effective against the South African variant of COVID-19 virus. (Telegraph)
  • Eli Lilly teams up with GSK and Vir biotech for COVID-19 antibody test. (FIERCE Biotech)
  • South Africa allows use of parasitic drug ivermectin in the treatment of COVID-19 among patients on compassionate grounds for a controlled access programme. (Bloomberg)
  • The Global Fund needs additional funding to continue supporting the coronavirus disease 2019 (COVID-19) response and mitigate the impact of the pandemic on HIV, tuberculosis, and malaria programs in the countries where it invests. After deploying all available COVID-19 funds, nearly $1 billion in total, most of it to sub-Saharan African countries, it has run out of funding. Without this support, implementer countries risk facing significant disruptions to their three disease programs while COVID-19 cases continue to rise. (Aidspan)
  • Overcoming neglect and finding ways to manage and control NTDs is a priority. (MSF)
  • The African Union has secured an additional 400million vaccine doses as reported by Africa CDC Director, John Nkengasong. (Africa News | Medical Express)
  • Johnson & Johnson COVID-19 vaccine shown to give greater protection against severe forms of COVID-19 disease. (Bloomberg)
  • Heparin that targets coronavirus spikes protecting interaction with ACE2 receptors have been found to show promise in COVID-19 management. (Medical Express)
  • New COVID-19 variants fuelling Africa’s second wave of COVID-19 infections. (WHO Africa Regional Office)
  • The EU Commissioner Kyriakides issued a statement on deliveries of vaccines by AstraZeneca pointing at probable need for approval on exports to third countries. (European Commission | IFPMA)
  • Pharmaceutical companies continue to inch forward when it comes to addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index, published Tuesday 26 January, 2021. (Access To Medicines Index)
  • KAPI Leadership Pays Courtesy Visit to the Principal Secretary (PS), Ministry of Health to deliberate on regulatory concerns plaguing the industry, medicines prices, COVID-19 vaccination plans among other issues in the industry. (Press Release)

Thank You!!!

Read More

KAPI Leadership Pays a Courtesy visit to the PS, Ministry of Health

On Tuesday 26th January 2021 the Kenya Association of Pharmaceutical Industry (KAPI) executive board led by the Chairperson, Willy Soriney paid a courtesy visit to the Principal Secretary, Ministry of Health Madam Susan Mochache. This was part of the associations’ stakeholder engagement mechanisms aimed at fostering collaborative spirit for the advancement of the health agenda for the Kenyan people.

KAPI is a membership based association representing research and development based biopharmaceutical companies in the country and plays a critical in role in promoting efficiencies in the pharmaceutical industry through policy advocacy, thought leadership, market intelligence and promotion of ethical business practices in the sector. These are geared towards ensuring Kenyans have access to high quality, safe and efficacious health products and technologies.

The discussions with the PS centred on prevailing concerns in the sector ranging from COVID-19 vaccines, taxation and pricing of medicines, local manufacturing of medicines and regulatory landscape. The association through its membership committed to collaborate with and support the ministry in its COVID-19 vaccine procurement and deployment strategy to ensure we served our social and moral obligation to our people.

Focusing on the cost of medicines which were noted to be higher than other countries in the region, it was noted that as a country we have unfavourable tax regimes that work against our common commitment to lower prices of medicines. It was noted that the Ministry of Health had taken a lead role in streamlining these with the establishment of a special committee spearheading the discussions to develop a plan that will ensure Kenyans can access safe, effective and quality healthcare products and technologies affordably as espoused in the UHC decree.

COVID-19 exposed shortfalls in the pharmaceutical industry especially with regard to reliance on imports of health products. This has brought attention and focus on promotion of local manufacturing as a strategy to secure supplies for the country. Acknowledging the need to support local manufacturing, KAPI leadership pointed out on the need for a strategic approach driven by incentives for local production and a favourable regulatory environment with stability & predictability. These are key drivers to investment and without investment it’s impossible to have a favourable local pharmaceutical industry.

The ministry commended such engagements acknowledging the critical role that the private sector has in supporting governments in realizing their agenda. “National development is a collaborative and joint agenda and the proactive approach by the association to drive a futuristic and sustainable agenda in the industry with the government is an indication of the ability to steer clear of the current hurdles and emerge victorious” stated the PS.

Read More

KAPI WEEKLY BRIEF: 18TH – 22ND JAN. 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • Larger trials needed to assess efficacy of tocilizumab in managing COVID-19. This follows conflicting findings from a study done in Brazil on the same drug published in the British Medical Journal (BMJ). (Reuters)
  • The US Government under President Biden and VP Kamala Harris recommits to WHO and plans to engage in supporting COVAX platform to support access to COVID-19 vaccines by poor countries. (AP News | AP News)
  • The World Health Organization (WHO) welcomes proposal by the European Commission to establish a treaty on Pandemic Preparedness keen on mobilizing political commitment at such critical times. (Reuters)
  • Three COVID-19 vaccines under final review by WHO for emergency use approval (Reuters)
  • “Equal access” to coronavirus vaccines is failing poor countries (POLITICO)
  • With emergence of new COVID-19 variants, vaccine efficacy against the new variants have been a concern. A study by Pfizer/BioNTech confirms efficacy of their vaccine against the UK variant of the virus. (Financial Times | STAT)
  • Global leaders make calls to rethink global public health governance for research and development on the backdrop of a raging pandemic. (South Center)
  • African children are consistently excluded from cancer clinical trials leading to high burden of cancer with no established therapies for this population. They are the unseen and the unheard. (BMJ Global Health)
  • WHO Executive Board discusses for the first time the importance of implementing mental health and psychosocial support services and activities. This will be expedited by endorsing the updated mental health action plan 2013 – 2030. (Relief Web)
  • Antibiotics overuse among pediatric patients which is rampant is driving the spike in antibiotic-resistant ‘superbugs’ in children’s hospitals. (Business Insider | Infectious Disease Society of America)
  • Drop in vaccination causes surge in global measles cases and deaths (JAMA)
  • Monthly Malaria Prophylaxis cuts child deaths in Sub-Saharan Africa (JAMA)
  • Progress towards ending TB at risk (Development Policy Center)
  • Gritstone Oncology a biotech company working on cancer vaccines adds COVID-19 vaccine to its pipeline with the hope of developing a vaccine effective against the entire family of viruses. (Fierce Biotech)
  • Single COVID-19 vaccine doses not as effective as earlier hoped. Study in Israel finds out. (Guardian)
  • COVID-19 vaccine shots to cost $3 to $ 10 under the African Union vaccine plan (Reuters)
  • COVAX is ready to deliver vaccines, WHO officials tell WHO Executive Board – but Regulatory Approvals still lagging for key COVAX products (Health Policy Watch)
  • Independent panel on pandemic preparedness and response presented a report on WHO with findings showing the agency is powerless with need for more funding and reforms. (France 24 | WSJ)
  • Executive Board members of the WHO call for diversification and reform of the agencies funding mechanisms to avoid budget crisis as was witnessed when US withdrew. (Health Policy Watch)
  • Nations propose strengthening of local manufacture of medicines and other health technologies to improve access to medicines during 148th Session of the WHO Executive Board Meeting. (WHO)
  • Africa CDC opens up COVID-19 vaccines pre-order programme for 55 AU countries (CGTN)
  • FDA approves first monthly injectable to treat HIV infection (STAT)

Thank You!!!

Read More

KAPI WEEKLY BRIEF: 11TH – 15TH JANUARY 2021

15th January 2021

Executive Summary

The Kenya Association of Pharmaceutical Industry (KAPI) is a membership organization, established in the late 1960s, representing biopharmaceutical manufacturers (or their local representatives) that through research invent and develop medicines and technologies (e.g., Biopharmaceuticals, Vaccine Healthcare, Medical devices, Diagnostics) that significantly improve people’s lives. KAPI represents the industry voice and promotes efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases.

Weekly Brief:

This is a roundup of news allied to the biopharmaceutical industry with a bearing on our mission to improve access to lifesaving health products and technologies for positive health outcomes.

  • World Health Organization (WHO) team of scientists arrived in Wuhan China on Thursday 14th January 2021 in plans to probe the origins of COVID-19. This comes after delays in being granted permission for the visit by the Chinese government. (The Hindu)
  • With the global COVID-19 pandemic still soaring, there have been a rise in reports of emergence of new variants of the virus. Some are associated with severe infections or rapid spread as has been noted with the South African and UK variants. Recently Kenya and the US also reported new variants. (Kenya – Nation Media; US – Financial Times)
  • German company Baxter Germany set to start the production of BioNTech/Pfizer Vaccine by early March (Reuters)
  • African Union (AU) secured an additional 270million doses of COVID-19 vaccines from Pfizer, AstraZeneca through the Serum Institute of India, and Johnson & Johnsons. (Reuters; The Presidency)
  • AstraZeneca filed for EU vaccine approval with additional information on safety, quality and efficacy. (Medical Express)
  • GlaxoSmithKline (GSK) and Vir Biotechnology are set to test their monoclonal antibody treatment for on mild to moderate COVID-19 patients within the first quarter of 2021. (Reuters)
  • Systems thinking and the application of systems thinking tools to real world problems is critical in the fight against Neglected Tropical Diseases (NTDs). (Yale Insights)
  • Progress made in the fight against superbug Acinetobacter baumannii through coupling of phages and antibiotics. (newsGP)
  • The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Speak Up Africa launched the Africa Young Innovators for Health Awards on 11th January 2021. This award seeks to fuel innovation and help advance promising healthcare solutions in the continent. (SciDev Net; Young Innovators for Health Award)

Thank You!!!

Read More

KAPI New Year Message – 2021

In a day, we’ll be crossing over from a significantly life-changing year to the next. The year 2020 has been life-changing to all of us; work from home, masking, social distancing, job losses, and loss of loved ones among others. It’s been extraordinary how we’ve adapted to the changes, pivoted our systems to cope and weathered the storm. Regardless of this, the battle isn’t yet won. COVID-19 is still with us and we’ve got to comply with the recommended measures of washing hands, wearing masks, social distancing and avoiding unnecessary travels & gatherings where possible.

When the first case of COVID-19 was reported in March, our lives were turned upside down with anxiety and uncertainty at its peak. As an association rooted on our mission, to promote efficiency in the pharmaceutical industry to ensure that medical products and healthcare technologies of the highest quality can be readily available for diagnosis, prevention and treatment of diseases, we have pivoted and continued to discharge our mandate through alternative means. Our physical meetings morphed to virtual meetings, stakeholders’ engagements took place virtually with a renewed commitment to leverage on our different strengths for improved efficiencies among others.

In September during the World Patient Safety Week, in conjunction with the Pharmacy and Poisons Board (PPB), Ecumenical Pharmaceutical Network (EPN), Pharmaceutical Society of Kenya (PSK), National Nurses Association of Kenya (NNAK), Kenya Medical Association (KMA), Hospital Pharmacists Association of Kenya (HOPAK) and The Aga Khan University Hospital (AKUH), we revamped our commitment to improve access to quality, safe and efficacious medical products and technologies as a prerequisite for quality healthcare & patient safety anchored on empowered, competent and protected healthcare workers. It also became evident that to foster this commitment, there’s need to continually engage with stakeholders and share insights for continuous improvement of care. As an association, we pledge to carry this into the next year.

Our members from the outset of the pandemic took up responsibility to engage with and contribute to the national response in different fronts. At institutional level, they adopted containment measures to safeguard their employees, reviewed their supply chain dynamics to buffer the sector from stock outs that were speculated. At community level, they were at the forefront in supporting communities through donations both to their communities and to professional associations to safeguard the wellbeing of healthcare practitioners among others. On global stage, our member companies have taken lead to develop therapeutics and vaccines for COVID-19. These include vaccines that are currently in the pipeline by Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson among others. These have been made possible by our common commitment as an industry to improve access to quality lifesaving healthcare products and technologies for a healthy populace. In one way or the other, you as a stakeholder have made it possible for us to get to this point and we appreciate you for that.

As we welcome a new year, having come to terms with our new normal it’s time to improve on our performance rooted on our commitment to safeguard the health of our people and improve access to quality, safe and efficacious healthcare products and technologies. To realize this, we know we can only dream so big and bank on your support to make it a reality. It’s because of this that we commit the New Year to a “Year of Redefining Collaboration in the Pharmaceutical Industry”.

In the coming year, we’ll be keen to revamp and establish new collaborative engagements with stakeholders; bring science behind the work we do as an industry closer to the people we do it for and derive value from it and most importantly do good for our communities. Good business is good for business and this will always be at the core of our work. Let’s walk the journey together.

Read More

Biopharmaceutical Companies Take Lead in COVID-19 Response in Kenya

As a membership organization driven by tenets of social responsibility and commitment to public health, in the wake of COVID-19 it is in our purview to drive a common agenda to flatten the curve of transmission, build concerted efforts to ensure uninterrupted supply of medicines, diagnostics and healthcare technologies.

George Onyango, Country Manager – GlaxoSmithKline handing over donation of surgical masks to KMPDU leadership

Additionally, our member companies have been in the forefront driving action through donations in kind and financially to curtail the economic impacts of this pandemic on the less fortunate in the society. Times of hardship are when you know your true compatriots and based on the responses we’ve seen among our members we are confident as a nation we’ll emerge victorious in the end. When we count our losses and learn from this pandemic, we hope we’ll have a robust, responsive and people-centric healthcare system.

During the peak infection period coupled with stringent containment measures our member companies were involved in different initiatives as outlined below:

  1. Johnson & Johnson – Through the Kenya COVID-19 Business Response Platform committed Kshs. 5 Million to the emergency response by the government in different interventions as was necessary through a common engagement platform.
  2. Reckitt Benckiser – Through the Kenya COVID-19 Business Response Platform donated products and services to the national response team to a tune of Kshs. 13 million i.e. Kshs. 10 million worth of soap and Kshs. 3.8 million for Media Tv for public awareness and sensitization.
  3. GlaxoSmithKline – Donated surgical masks worth Kshs. 3 million to frontline healthcare workers through the Kenya Medical Practitioners Pharmacists and Dentists Union (KMPDU) to contain infection of health workers following global shortage of PPEs.
  4. AstraZeneca – Donated 35,000 surgical masks to the government to equip healthcare workers in the different isolation facilities.
  5. Bayer East Africa – Provided free IEC materials and hand sanitizers. These included fliers and posters with relevant COVID-19 information to sensitize the public and communities within which we operate both to both the employees and members of the public. Donation of five (5) handwashing water tanks to the Kenyatta National Hospital (KNH) to encourage handwashing as a preventive measure against COVID-19. The company also supported Tenwek Hospital in Bomet County with assorted PPEs including masks and gowns as well as thermos-guns and hand sanitizers.
  6. Novartis – With COVID-19, attention on other medical conditions have been at stake. On this account, when the world was marking World Sickle Cell Disease, as part of contribution to health systems strengthening and promoting care to Sickle Cell Disease Patients, Novartis offered support to the Ministry of Health, Kenya in commemorating the day. The support went into development of guidelines for the management of sickle cell disease as reported by the Chief Administrative Secretary of Health, Dr Rashid Aman.
Bayer Team at Tenwek Hospital as they donated PPEs to the facility.

These among many other interventions that were coordinated by industry leaders played a key role in shaping the trajectory of the disease in the country.

Read More